whitepaper Whitepaper: Biomarkers and mechanisms of toxicity 23 February 2021 | By Eurofins Discovery Phenotypic profiling identifies biomarkers and mechanisms of toxicity.
news Analysis conducted on glycan structure from sheep prion strains 22 February 2021 | By Victoria Rees (Drug Target Review) Using liquid chromatography/mass spectrometry, researchers have revealed no major differences in glycan structures in two prion strains.
article NOX5: a novel target for sensitising melanoma to therapies 19 February 2021 | By Hannah Balfour (Drug Target Review) Vito Quaranta, professor of biochemistry and pharmacology, discusses how cancerous cells adopting novel mechanisms of energy production could be sensitised to existing therapies with a focus on melanoma.
news UK Government to fund four studies investigating long COVID 19 February 2021 | By Victoria Rees (Drug Target Review) The UK Government will give £18.5 million in funding to four studies researching the causes and potential treatments of long COVID.
news D614G Spike mutation makes SARS-CoV-2 up to eight times more infectious 18 February 2021 | By Victoria Rees (Drug Target Review) A study has shown the D614G mutation in the Spike protein of SARS-CoV-2 makes the coronavirus more transmissible than the original virus from China.
news RNA sequencing reveals insight into tuberculosis infection 17 February 2021 | By Victoria Rees (Drug Target Review) Using single-cell RNA sequencing, researchers have shown that interferon response is correlated with tuberculosis progression.
news Mutations in SARS-CoV-2 Spike could lead to greater infectivity, study shows 16 February 2021 | By Victoria Rees (Drug Target Review) Comparing the original SARS-CoV-2 Spike protein with a mutated version, researchers have potentially revealed why the mutated version is dominant.
news Researchers discover process viruses use to block antiviral immune response 16 February 2021 | By Victoria Rees (Drug Target Review) A team has revealed that viruses ‘hijack’ a molecular process in the cell, inhibiting the body’s response to viral infection.
news Protein sequences provide insight to SARS-CoV-2 infection, study shows 12 February 2021 | By Victoria Rees (Drug Target Review) Research has shown that ACE2 and several integrins containing SLiMs are involved in SARS-CoV-2 infection, presenting new therapeutic targets.
whitepaper ebook: Vaccines in the digital age 11 February 2021 | By IDBS In this ebook, we’ll see how digitally enabling your organisation can increase capacity and improve vaccine production.
news Scientists reveal four discoveries about early SARS-CoV-2 infection 11 February 2021 | By Victoria Rees (Drug Target Review) Researchers studying SARS-CoV-2 at the individual cellular level have made four major discoveries about early infection from the coronavirus.
whitepaper Whitepaper: Profiling oncology candidates 9 February 2021 | By Eurofins Discovery Profiling oncology drug candidates through complementary in vitro assays and in vivo models to better understand their potential clinical applications.
whitepaper Whitepaper: Automated cell culture and screening 8 February 2021 | By Ncardia This whitepaper describes the automated culturing of hiPSC-derived cells for high-throughput phenotypic screening, using validated phenotypic assays.
news Flaw found in lab models used to study human blood-brain barrier 8 February 2021 | By Victoria Rees (Drug Target Review) Researchers have uncovered a flaw in lab models used to study the human blood-brain barrier and a potential strategy to correct the error.
article Could downregulating the Drp1 protein prevent Alzheimer’s progression? 4 February 2021 | By Hannah Balfour (Drug Target Review) In this article, we explore the findings of a study that suggests a newly identified pathway, the Drp1-HK1-NLRP3 signalling axis, could be a promising target for therapies to prevent Alzheimer’s disease progression.
